List of works - Christopher A. Klebanoff

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

scientific article (publication date: November 2016)

Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells

scientific article

Akt inhibition enhances expansion of potent tumor-specific lymphocytes with memory cell characteristics.

scientific article

BACH2 regulates CD8(+) T cell differentiation by controlling access of AP-1 factors to enhancers

scientific article published on 09 May 2016

BACH2 represses effector programs to stabilize T(reg)-mediated immune homeostasis.

scientific article published on 02 June 2013

Bedside to bench and back again: how animal models are guiding the development of new immunotherapies for cancer

scientific article

CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells.

scientific article

Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells

scientific article

Cish actively silences TCR signaling in CD8+ T cells to maintain tumor tolerance

scientific article

Customizing Functionality and Payload Delivery for Receptor-Engineered T Cells

scientific article published in October 2016

Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice

scientific article

Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity

scholarly article

Fas/CD95 prevents autoimmunity independently of lipid raft localization and efficient apoptosis induction

scientific article published on 23 December 2016

Generation of clinical-grade CD19-specific CAR-modified CD8+ memory stem cells for the treatment of human B-cell malignancies.

scientific article published on 25 May 2016

Genetic engineering of murine CD8+ and CD4+ T cells for preclinical adoptive immunotherapy studies.

scientific article

Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy.

scientific article

IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells

scientific article

IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy

scientific article published on 14 February 2008

Immunogenicity and therapeutic targeting of a public neoantigen derived from mutated PIK3CA

scientific article published on 28 April 2022

Immunotherapy: Treatment of aggressive lymphomas with anti-CD19 CAR T cells.

scientific article published on 11 November 2014

Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function.

scientific article published on 16 September 2013

Inhibiting retinoic acid signaling ameliorates graft-versus-host disease by modifying T-cell differentiation and intestinal migration

scientific article published on 27 June 2013

Ionic immune suppression within the tumour microenvironment limits T cell effector function.

scientific article published on 14 September 2016

Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer

scientific article published on April 2017

Lineage relationship of CD8(+) T cell subsets is revealed by progressive changes in the epigenetic landscape

scientific article

Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels.

scientific article published on 14 March 2017

Memory T cell-driven differentiation of naive cells impairs adoptive immunotherapy

scientific article published on 14 December 2015

Mitochondrial Membrane Potential Identifies Cells with Enhanced Stemness for Cellular Therapy.

scientific article published on 7 December 2015

Oxygen Sensing by T Cells Establishes an Immunologically Tolerant Metastatic Niche.

scientific article

Paths to stemness: building the ultimate antitumour T cell.

scientific article

Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (29-30 November, 2017, Naples, Italy).

scientific article published on 11 July 2018

Pharmacologic induction of CD8+ T cell memory: better living through chemistry

scientific article published on December 2009

Programming tumor-reactive effector memory CD8+ T cells in vitro obviates the requirement for in vivo vaccination.

scientific article published on 26 June 2009

Prospects for gene-engineered T cell immunotherapy for solid cancers. ⬇️

scientific article

Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic Melanoma

scientific article

Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells

scientific article

Retinoic acid controls the homeostasis of pre-cDC-derived splenic and intestinal dendritic cells

scientific article published on 02 September 2013

Shared cancer neoantigens: Making private matters public.

scientific article published on 21 December 2017

Silencing stemness in T cell differentiation.

scientific article

Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy.

scientific article

Stubborn Tregs limit T-cell therapy

scientific article published on 01 September 2012

T cell receptor-based cancer immunotherapy: Emerging efficacy and pathways of resistance

scientific article published on 01 July 2019

T cell stemness and dysfunction in tumors are triggered by a common mechanism

scientific article

Th17 cells are long lived and retain a stem cell-like molecular signature

scientific article

The transcription factor BACH2 promotes tumor immunosuppression.

scientific article published on 5 January 2016

Therapeutic cancer vaccines: are we there yet? ⬇️

scientific article published on January 1, 2011

Transcriptional profiles reveal a stepwise developmental program of memory CD8(+) T cell differentiation.

scientific article published on November 2014

Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class II-Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3.

scientific article published on 15 August 2017

Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study

scientific article

Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells.

scientific article

Type I cytokines synergize with oncogene inhibition to induce tumor growth arrest

scientific article

Vaccine-stimulated, adoptively transferred CD8+ T cells traffic indiscriminately and ubiquitously while mediating specific tumor destruction.

scientific article

miR-155 augments CD8+ T-cell antitumor activity in lymphoreplete hosts by enhancing responsiveness to homeostatic γc cytokines.

scientific article

List of works by Christopher A. Klebanoff

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells

Akt inhibition enhances expansion of potent tumor-specific lymphocytes with memory cell characteristics.

BACH2 regulates CD8(+) T cell differentiation by controlling access of AP-1 factors to enhancers

BACH2 represses effector programs to stabilize T(reg)-mediated immune homeostasis.

Bedside to bench and back again: how animal models are guiding the development of new immunotherapies for cancer

CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells.

Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells

Cish actively silences TCR signaling in CD8+ T cells to maintain tumor tolerance

Customizing Functionality and Payload Delivery for Receptor-Engineered T Cells

Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice

Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity

Fas/CD95 prevents autoimmunity independently of lipid raft localization and efficient apoptosis induction

Generation of clinical-grade CD19-specific CAR-modified CD8+ memory stem cells for the treatment of human B-cell malignancies.

Genetic engineering of murine CD8+ and CD4+ T cells for preclinical adoptive immunotherapy studies.

Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy.

IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells

IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy

Immunogenicity and therapeutic targeting of a public neoantigen derived from mutated PIK3CA

Immunotherapy: Treatment of aggressive lymphomas with anti-CD19 CAR T cells.

Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function.

Inhibiting retinoic acid signaling ameliorates graft-versus-host disease by modifying T-cell differentiation and intestinal migration

Ionic immune suppression within the tumour microenvironment limits T cell effector function.

Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer

Lineage relationship of CD8(+) T cell subsets is revealed by progressive changes in the epigenetic landscape

Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels.

Memory T cell-driven differentiation of naive cells impairs adoptive immunotherapy

Mitochondrial Membrane Potential Identifies Cells with Enhanced Stemness for Cellular Therapy.

Oxygen Sensing by T Cells Establishes an Immunologically Tolerant Metastatic Niche.

Paths to stemness: building the ultimate antitumour T cell.

Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (29-30 November, 2017, Naples, Italy).

Pharmacologic induction of CD8+ T cell memory: better living through chemistry

Programming tumor-reactive effector memory CD8+ T cells in vitro obviates the requirement for in vivo vaccination.

Prospects for gene-engineered T cell immunotherapy for solid cancers. ⬇️

Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic Melanoma

Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells

Retinoic acid controls the homeostasis of pre-cDC-derived splenic and intestinal dendritic cells

Shared cancer neoantigens: Making private matters public.

Silencing stemness in T cell differentiation.

Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy.

Stubborn Tregs limit T-cell therapy

T cell receptor-based cancer immunotherapy: Emerging efficacy and pathways of resistance

T cell stemness and dysfunction in tumors are triggered by a common mechanism

Th17 cells are long lived and retain a stem cell-like molecular signature

The transcription factor BACH2 promotes tumor immunosuppression.

Therapeutic cancer vaccines: are we there yet? ⬇️

Transcriptional profiles reveal a stepwise developmental program of memory CD8(+) T cell differentiation.

Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class II-Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3.

Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study

Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells.

Type I cytokines synergize with oncogene inhibition to induce tumor growth arrest

Vaccine-stimulated, adoptively transferred CD8+ T cells traffic indiscriminately and ubiquitously while mediating specific tumor destruction.

miR-155 augments CD8+ T-cell antitumor activity in lymphoreplete hosts by enhancing responsiveness to homeostatic γc cytokines.